What is the recommended regimen for antenatal corticosteroids (ACS) in pregnant women at risk of preterm delivery?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Antenatal Corticosteroid Regimen for Preterm Delivery

The recommended regimen is betamethasone 12 mg intramuscularly as two doses given 24 hours apart for pregnant women at risk of preterm delivery. 1, 2

Standard Dosing Protocol

Betamethasone 12 mg IM × 2 doses, 24 hours apart is the evidence-based standard regimen endorsed by both the Society for Maternal-Fetal Medicine and the American College of Obstetricians and Gynecologists. 1, 2

Gestational Age-Specific Recommendations

For 24 0/7 to 34 6/7 weeks gestation:

  • Administer betamethasone 12 mg IM × 2 doses, 24 hours apart, to all women at high risk of preterm delivery within 7 days 2, 3
  • This represents a GRADE 1A recommendation with high-certainty evidence 1, 2

For 34 0/7 to 36 6/7 weeks gestation (late preterm):

  • Offer betamethasone 12 mg IM × 2 doses, 24 hours apart, to women with singleton pregnancies at high risk of delivery within 7 days and before 37 weeks 1
  • High-risk criteria include: preterm labor with cervical dilation ≥3 cm or ≥75% effacement, spontaneous rupture of membranes, or anticipated delivery for maternal/fetal indications (e.g., preeclampsia) 4

Clinical Benefits by Outcome

Respiratory outcomes:

  • Reduces respiratory distress syndrome by 29% (RR 0.71) 3
  • Decreases need for respiratory support by 20% (11.6% vs 14.4%; RR 0.80) 2, 4
  • Reduces severe respiratory morbidity by 33% (8.1% vs 12.1%; RR 0.67) 2, 4

Mortality outcomes:

  • Reduces neonatal death by 22% (RR 0.78) 3
  • Reduces perinatal death by 15% (RR 0.85) 3

Neurologic outcomes:

  • Probably reduces intraventricular hemorrhage by 42% (RR 0.58) 3
  • Probably reduces developmental delay in childhood by 49% (RR 0.51) 3

Critical Contraindications

Absolute contraindication:

  • Do NOT administer to pregnant patients with pregestational diabetes mellitus due to significantly increased risk of neonatal hypoglycemia 1, 4

Relative contraindication:

  • Do not administer to patients with low likelihood of delivery before 37 weeks gestation 1, 4

Timing Considerations

Optimal benefit window:

  • Maximum benefit occurs when delivery happens 24 hours to 7 days after administration 2
  • Benefits extend beyond 7 days but are reduced 5

Single course only:

  • Administer only one course of antenatal corticosteroids 2, 6
  • Routine repeat or "rescue" courses are not recommended for the standard gestational age range 2, 6
  • Repeat courses may be considered in special circumstances for women who remain undelivered beyond 7 days and are at continued high risk, though evidence is limited 5

Special Populations

May consider administration in select cases (GRADE 2C):

  • Multiple gestations reduced to singleton on or after 14 0/7 weeks 1, 4
  • Fetal anomalies 1, 4
  • Expected delivery in <12 hours 1, 4

Microcystic congenital pulmonary airway malformation with hydrops:

  • Use betamethasone 12.5 mg IM every 24 hours for 2 doses 7

Maternal Safety Profile

Maternal outcomes show:

  • Little to no difference in maternal death (RR 1.19) 3
  • Little to no difference in chorioamnionitis (RR 0.86) 3
  • Little to no difference in endometritis (RR 1.14) 3
  • Little to no effect on cesarean birth rate (RR 1.03) 4

Neonatal Monitoring Requirements

Hypoglycemia surveillance:

  • Neonatal hypoglycemia is more common with betamethasone but typically mild and self-limited 2, 7, 4
  • 93% of hypoglycemia cases resolve within 24 hours 2, 7
  • Monitor blood glucose in all exposed neonates 2, 7

Common Pitfalls to Avoid

Avoid administering when:

  • Delivery is unlikely before 37 weeks (leads to unnecessary exposure) 1
  • Patient has pregestational diabetes (increases neonatal hypoglycemia risk) 1
  • Multiple courses are given routinely without specific indication 2, 6

Ensure proper timing:

  • Administer when delivery is anticipated within 7 days for maximum benefit 1, 2
  • Do not delay necessary delivery to complete the 24-hour dosing interval if maternal or fetal compromise exists 6

Patient Counseling

Patients must be counseled about:

  • Potential short-term benefits for respiratory outcomes and survival 1
  • Risk of neonatal hypoglycemia, particularly in diabetic mothers 1
  • Long-term neurodevelopmental effects remain uncertain and require ongoing research 1, 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Antenatal Corticosteroid Therapy for Preterm Delivery

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Betamethasone Dosing for Fetal Lung Maturation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Betamethasone Dosing for Fetal Lung Lesions

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.